Psychotic experiences and general medical conditions: a cross-national analysis based on 28,002 respondents from 16 countries in the WHO World Mental Health Surveys

Short title: Psychotic experiences and general medical conditions

Kate M. Scott[1], Sukanta Saha[2], Carmen C.W. Lim[2], Sergio Aguilar-Gaxiola[3], Ali Al-Hamzawi[4], Jordi Alonso[5], Corina Benjet[6], Evelyn J. Bromet[7], Ronny Bruffaerts[8], José Miguel Caldas-de-Almeida[9], Giovanni de Girolamo[10], Peter de Jonge[11], Louisa Degenhardt[12], Silvia Florescu[13], Oye Gureje[14], Josep M. Haro[15], Chiyi Hu[16], Elie G. Karam[17], Viviane Kovess-Masfety[18], Sing Lee[19], Jean-Pierre Lepine[20], Zeina Mneimneh[21], Fernando Navarro-Mateu[22], Marina Piazza[23], José Posada-Villa[24], Nancy A. Sampson[25], Juan Carlos Stagnaro[26], Ronald C. Kessler[25], John J. McGrath[27*] on behalf of the WHO World Mental Health Survey Collaborators[+]

[1] Department of Psychological Medicine, University of Otago, Dunedin, New Zealand
[2] Queensland Centre for Mental Health Research and Queensland Brain Institute, The University of Queensland, St. Lucia, Queensland, Australia
[3] Center for Reducing Health Disparities, UC Davis Health System, Sacramento, California, USA
[4] College of Medicine, Al-Qadisiya University, Diwaniya governorate, Iraq
[5] Health Services Research Unit, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Pompeu Fabra University (UPF), Barcelona, Spain; and CIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
[6] Department of Epidemiologic and Psychosocial Research, National Institute of Psychiatry Ramón de la Fuente, Mexico City, Mexico
[7] Department of Psychiatry, Stony Brook University School of Medicine, Stony Brook, New York, USA
[8] Universitair Psychiatrisch Centrum - Katholieke Universiteit Leuven (UPC-KUL), Campus Gasthuisberg, Leuven, Belgium
[9] Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC), NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal
[10] Unit of Epidemiological and Evaluation Psychiatry, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)-St. John of God Clinical Research Centre, Via Pilastroni 4, Brescia, Italy
[11] Developmental Psychology, Department of Psychology, Rijksuniversiteit Groningen, Groningen, NL; Interdisciplinary Center Psychopathology and Emotion Regulation, Department of Psychiatry, University Medical Center Groningen, Groningen, NL
[12] National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia
[13] National School of Public Health, Management and Development, Bucharest, Romania
[14] Department of Psychiatry, University College Hospital, Ibadan, Nigeria
[15] Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain
[16] Shenzhen Institute of Mental Health & Shenzhen Kangning Hospital, Shenzhen, China

[17] *Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University, Beirut, Lebanon; Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center, Beirut, Lebanon; Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon*
[18] *Ecole des Hautes Etudes en Santé Publique (EHESP), EA 4057, Paris Descartes University, Paris, France*
[19] *Department of Psychiatry, Chinese University of Hong Kong, Tai Po, Hong Kong*
[20] *Hôpital Lariboisière- Fernand Widal, Assistance Publique Hôpitaux de Paris; Universités Paris Descartes-Paris Diderot; INSERM UMR-S 1144, Paris, France*
[21] *Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, Michigan, USA*
[22] *UDIF-SM, Subdirección General de Planificación, Innovación y Cronicidad, Servicio Murciano de Salud. IMIB-Arrixaca. CIBERESP-Murcia, Murcia, Spain*
[23] *Universidad Cayetano Heredia, Lima, Peru; National Institute of Health, Lima, Peru*
[24] *Colegio Mayor de Cundinamarca University, Faculty of Social Sciences, Bogota, Colombia*
[25] *Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts, USA*
[26] *Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad de Buenos Aires, Argentina*
[27] *Queensland Centre for Mental Health Research, and Queensland Brain Institute, University of Queensland, St. Lucia, Queensland, Australia; and National Centre for Register-based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark*

[+=]WHO World Mental Health Survey Collaborators are listed in the Appendix

Address for correspondence: Prof John McGrath j.mcgrath@uq.edu.au

ABSTRACT

Background. Previous work has identified associations between psychotic experiences (PEs) and general medical conditions (GMCs) but their temporal direction remains unclear as does the extent to which they are independent of comorbid mental disorders.

Methods. 28,002 adults in 16 countries from the WHO World Mental Health Surveys were assessed for PEs, GMCs, and 21 DSM-IV mental disorders. Discrete-time survival analyses were used to estimate the associations between PEs and GMCs with various adjustments.

Results. After adjustment for comorbid mental disorders, temporally prior PEs were significantly associated with subsequent onset of 8/12 GMCs (arthritis, back or neck pain, frequent or severe headache, other chronic pain, heart disease, high blood pressure, diabetes, and peptic ulcer) with odds ratios ranging from 1.3 (95% CI=1.1-1.5) to 1.9 (95% CI=1.4-2.4). In contrast, only three GMCs (frequent or severe headache, other chronic pain, and asthma) were significantly associated with subsequent onset of PEs after adjustment for comorbid GMCs and mental disorders, with odds ratios ranging from 1.5 (95% CI = 1.2-1.9) to 1.7 (95% CI = 1.2-2.4).

Conclusions. PEs were associated with the subsequent onset of a wide range of general medical conditions, independent of comorbid mental disorders. There were also associations between some medical conditions (particularly those involving chronic pain) and subsequent PEs. Although these findings will need to be confirmed in prospective studies, clinicians should be aware that psychotic symptoms may be risk markers for a wide range of adverse health outcomes. Whether PEs are causal risk factors will require further research.

Key words: Psychotic experiences, general medical conditions, physical disorders, mental disorders, asthma, arthritis, pain, headache, heart disease, diabetes

Introduction

There is now clear evidence demonstrating that psychotic experiences (PEs) in the absence of psychotic disorders are common in the general population (Linscott and van Os, 2013, McGrath *et al.*, 2015). Recent research showing that those with PEs are at increased risk of premature mortality (Sharifi *et al.*, 2015) heightens interest in the relationship between PEs and general medical conditions (GMCs). Although this is a relatively new topic of investigation, evidence is accruing that PEs are associated with a range of GMCs such as heart disease, diabetes, arthritis, asthma, dental problems, hearing loss, and chronic pain conditions (Saha *et al.*, 2011a, Moreno *et al.*, 2013, Koyanagi and Stickley, 2015a, Oh and DeVylder, 2015, Koyanagi *et al.*, 2016b, Stubbs *et al.*, 2016, Koyanagi *et al.*, 2017). Several studies have also found associations between PEs and sleep problems (Koyanagi and Stickley, 2015b, Thompson *et al.*, 2015, DeVylder and Kelleher, 2016, Oh *et al.*, 2016, Andorko *et al.*, 2017), and a recent randomized controlled trial found that treatment of insomnia reduced the prevalence of PEs (Freeman *et al.*, 2017).

Two questions arise in relation to these PE-GMC associations. The first question is whether they are independent of comorbid common mental disorders given that (i) PEs are associated with common mental disorders (DeVylder *et al.*, 2014, McGrath *et al.*, 2016b) and (ii) that common mental disorders are associated with GMCs (Lawrence *et al.*, 2013, Scott *et al.*, 2016). Only a very small number of studies have examined this question and the results are equivocal. In general, these studies find that associations between PEs and GMCs are attenuated after adjustment for comorbid mental disorders but that some associations do persist (Saha *et al.*, 2011a, Moreno *et al.*, 2013, Oh and DeVylder, 2015). In a study of PEs and pain conditions, however, the associations lost significance after adjustment for comorbid mental disorders (Koyanagi *et al.*, 2016b).

The second important question concerns the temporal direction of associations. Prior studies have not been able to consider the temporal sequencing of PEs and GMCs; that is, whether temporally prior PEs are associated with subsequent onset of GMCs, and/or whether GMCs are associated with subsequent first onset of PEs. Mindful that certain GMCs typically have an early onset (e.g. asthma) while many have later onset (e.g. heart disease, cancer), understanding the extent to which these PEs and GMCs associations follow a specific temporal sequence has important theoretical, clinical and public health significance. Ideally, this kind of investigation of temporal sequence should be undertaken in prospective studies. However, this would require very large cohorts with information on PEs, mental disorders and GMCs followed for decades (given the typically early onset of PEs and mental disorders, and later onset of most GMCs). To our knowledge, no such data are presently

available. Therefore, in order to examine the temporal direction of PEs and GMCs, we have used retrospectively collected data from the World Mental Health Surveys (Kessler and Üstün, 2004) on age-at onset of PEs, mental disorders and GMCs.

The specific aims of this study were to examine: (a) whether PEs are associated with subsequent onset/diagnosis of GMCs; (b) whether GMCs are associated with subsequent onset of PEs; c) whether these associations are independent of a wide range of antecedent mental disorders; and d) the role of severity of PEs (number of PE types, annualized frequency of PEs) in the association with GMCs.

Method

Samples

The WHO World Mental Health (WMH) surveys are a coordinated set of community surveys generally administered to adult respondents (18 years and over) in countries throughout the world (Kessler and Üstün, 2004). Data for this study were drawn from the 16 WMH surveys that included both the Psychosis Module and items related to GMCs (N=28,002). These 16 surveys are distributed across North and South America (Argentina, Colombia, Mexico, Peru, USA); the Middle East (Iraq); Asia (Shenzhen in the People's Republic of China); the South Pacific (New Zealand); and Europe (Belgium, France, Germany, Italy, the Netherlands, Portugal, Romania, Spain). The majority of these surveys were based on multi-stage, clustered area probability household sampling designs, the exceptions being Belgium, Germany and Italy, which used municipal resident registries to select respondents (Supplementary table S1). The weighted (by sample size) average response rate across the 16 surveys was 71.3%.

In order to focus on the correlates of PEs in those without psychotic disorders, we made the *a priori* decision to exclude individuals who had PEs but who also screened positive for possible schizophrenia/psychosis and manic-depression/mania. Thus, in keeping with previous studies of PEs (Saha *et al.*, 2011b, McGrath *et al.*, 2015, McGrath *et al.*, 2016a, McGrath *et al.*, 2016b), we excluded respondents who (a) reported *(1) schizophrenia/psychosis* or *(2) manic-depression/mania* in response to the question "*What did the doctor say was causing (this/these) experiences?"* (respondents with these disorders who did not report PEs were not excluded); and (b) those who ever took an antipsychotic medication for these symptoms. This resulted in the exclusion of 124 respondents (0.4%), leaving 28,002 respondents for this study.

Procedures

WMH interviews were conducted in the homes of respondents by trained lay interviewers. Informed consent was obtained before beginning interviews in all countries. Procedures for obtaining informed consent and protecting individuals (ethical approvals) were approved and monitored for compliance by the institutional review boards of the collaborating organisations in each country. Standardised interviewer training and quality control procedures were used consistently in the surveys. Full details of these procedures are described elsewhere (Kessler *et al.*, 2006, Kessler and Üstün, 2008).

Interviews were administered face to face in two parts. Part 1, which assessed a core set of mental disorders was administered to all respondents. Part 2 of the interview which assessed additional mental disorders, questions about PEs, and GMCs, was administered to respondents who met lifetime criteria for any Part I disorder, and a random proportion of the remaining sample of those without any Part 1 disorders. Part 2 respondents were weighted by the inverse of their probability of selection to adjust for differential sampling, and therefore provide representative data on the target adult general population. Details about sampling methods are available elsewhere (Kessler and Üstün, 2004). Additional weights were used to adjust for differential probabilities of selection within households, nonresponse, and to match the samples to population socio-demographic distributions in each country.

Measures

The WMH surveys administered the WHO Composite International Diagnostic Interview (CIDI)(Kessler and Üstün, 2008), a validated fully-structured diagnostic interview designed to assess the prevalence and correlates of a wide range of mental disorders according to the definitions and criteria of both the DSM-IV and ICD-10 diagnostic systems. Translation, back-translation, and harmonisation protocols were used to adapt the CIDI for use in each participating country.

General medical conditions (GMCs): General medical conditions were assessed based on a series of questions adapted from the US National Health Interview Survey. Twelve conditions were assessed in this study. Respondents were asked if they had a lifetime history of symptom-based conditions (i.e., arthritis or rheumatism, chronic back or neck pain, frequent or severe headaches, any other chronic pain or stroke) and whether they were ever told by a doctor or other health professional that they had a series of medical conditions (e.g. heart disease, cancer, diabetes mellitus,

hypertension, asthma, other chronic lung diseases or peptic ulcer). For all of these conditions reported, respondents were also asked how old they were when they were first diagnosed with the condition or first experienced the symptomatic condition. Prior research has demonstrated good concordance between self-reported illness and medical records (Baumeister *et al.*, 2010).

Psychotic experiences (PEs): The CIDI Psychosis Module included questions about six PE types – two related to hallucinatory experiences and four related to delusional experiences. We excluded PEs experienced while dreaming, half-asleep or under the influence of alcohols or drugs (Supplementary tables S2a, S2b). In this paper, we present estimates of GMCs for "Any PEs" only (i.e. not individual types of PEs). In addition, we included two key PE variables: (a) number of PE types; and (b) an annualized frequency metric based on the frequency of PE episodes per year. We derived the latter by dividing the total number of PE episodes by the time since onset of the first PE (age at interview minus age-at onset plus 1 in order to avoid zero as a denominator). We used the median threshold to dichotomize this metric. Age-at-onset of respondents with PEs was also assessed.

Mental disorders: The WMH version of the CIDI assessed lifetime history of 21 mental disorders broadly classified into *mood disorders*; *anxiety disorders; behavior disorders*; *eating disorders* and *substance use disorders* (see Supplementary table S2c). Full details are given in several WMH publications including two of our recent papers (McGrath *et al.*, 2016b, McGrath *et al.*, 2017). Clinical reappraisal studies indicate that lifetime diagnoses based on the CIDI have good concordance with diagnoses based on blinded clinical interviews (Haro *et al.*, 2006). In keeping with our previous research, standardised diagnostic hierarchy rules among the disorders assessed were applied where appropriate (McGrath *et al.*, 2016b).

Statistical Analysis

Descriptive statistics were used for the lifetime prevalence of PEs, GMCs, and GMCs among respondents with and without PEs. Respondents with GMCs that developed after PEs, and GMCs that developed before PEs were compared using weighted Rao-Scott Chi-Square test. Discrete-time survival models with person-year as the unit of analysis were used to investigate the temporal sequencing of associations between PEs and GMCs. When examining the predictive relationship between temporally prior PEs and the subsequent onset of GMCs, PEs that occurred in the same year as GMCs or following GMCs were excluded. Those without GMCs were censored at their age at interview. We used any PEs, number of PE types, and annualized frequency of PEs in base models as predictors of subsequent GMCs adjusting for; (a) age at interview, sex, person-year, and country; (b)

in multivariate models we additionally adjusted for 21 antecedent mental disorders (i.e. disorders occurring antecedent or intervening between PEs and GMCs). Likewise, when examining the relationship between temporally prior GMCs and subsequent onset of PEs, we excluded GMCs that occurred in the same year as PEs onset or following PEs. Those without PEs were censored at their age at interview. To examine the associations between GMCs and subsequent onset of PEs, a series of base and multivariate models (M1 – M5) was developed. For the base models, we incorporated one GMC at a time to predict for subsequent PEs adjusting for age at interview, gender, person-year and country. For multivariate models, we incorporated: (a) all GMCs types simultaneously (Model M1), (b) number of GMCs without any information about type (Model M2), (c) type and number of GMCs (Model M3), and (d) type and number of GMCs with adjustments for antecedent mental disorders (Model M4) in predicting subsequent PE onset. Models M3 and M4 allow for non-additive relationships between type and number such that the effect of number of GMCs may vary across types. Finally, as there are associations between smoking and both (a) GMCs (Doll, 1998, Keto *et al.*, 2016) and (b) PEs (Koyanagi *et al.*, 2016a), we undertook post-hoc analyses where we adjusted for lifetime occurrence of tobacco use (yes/no) as an additional variable with all other adjustments.

As the WMH data are both clustered and weighted, the design based Taylor series linearization implemented in SUDAAN software (RTI International, 1999) was used to estimate the standard errors and evaluate the statistical significance of the coefficients. Survival coefficients and their standard errors were exponentiated to generate ORs and 95% confidence intervals. All significance tests were evaluated using 0.05-level two-sided tests.

Results

Characteristics of the sample

The age range of the combined cross-national sample was 18-99 (supplementary Table 1), with a weighted mean age of 41.9 years (SE=0.2) and median age of 38.2 years (IQR= 26.5-53.3). Females accounted for 51.6% of the sample (SE=0.4).

Prevalence of general medical conditions (GMCs)

The weighted prevalence of PEs in this sample was 5.0% (SE=0.2). The lifetime prevalence of GMCs ranged from 1.3% (SE = 0.1) for other chronic lung diseases to 24.3% (SE = 0.4) for back or neck pain (Table 1). When divided into those with or without PEs, the prevalence of GMCs was consistently

higher for those with lifetime PEs compared to those without. Among the subset of respondents with both lifetime GMC and PEs, a large proportion of respondents experienced PEs prior to GMCs, consistent with the later age of onset of most of the GMCs examined in this study (Table 1; see also supplementary table S4).

Associations between PEs and subsequent onset of general medical conditions

We first examined the associations between PEs and subsequent onset of GMCs (Table 2). Temporally prior PEs were significantly associated with subsequent first onset of 8 of the 12 GMCs (i.e., arthritis, back or neck pain, other chronic pain, frequent or severe headache, heart disease, high blood pressure, diabetes, and peptic ulcer). The odds ratios (ORs) ranged from 1.4 (95% CI=1.2-1.7) for high blood pressure to 2.3 (95% CI=1.8-3.0) for other chronic pain. There was a significant dose-response relationship between number of PE types and all the eight GMCs indicating increasing odds of GMCs with increasing number of PE types (χ^2 ranged between 10.5 and 73.3). Those with more frequent annualized PEs (> 0.3 episodes per year) compared to those with ≤ 0.3 episodes per year had approximately two-fold increased odds of developing subsequent GMCs. After adjusting for antecedent mental disorders, the majority of the associations between PEs and these eight GMCs lessened in magnitude but remained statistically significant.

Associations between temporally prior general medical conditions and subsequent onset of PEs

Next, we examined the associations between temporally prior GMCs and the subsequent onset of PEs (Table 3). In the base model, 7 of the 12 GMCs (arthritis, back or neck pain, frequent or severe headache, other chronic pain, high blood pressure, asthma, and peptic ulcer) were significantly associated with increased odds of any PEs. The ORs ranged between 1.7 and 2.7 with the highest OR for other chronic pain (OR = 2.7, 95% CI = 2.1-3.5) followed by frequent or severe headache (OR = 2.1, 95% CI = 1.7-2.5). When we adjusted for comorbidity of other GMCs (M1), five of the GMCs (arthritis, back or neck pain, frequent or severe headache, other chronic pain, and asthma) remained statistically significant. Next, after fitting the model that included number as well as type of GMCs (M3), the significant associations of these conditions with PE onset persisted. Finally, when we adjusted for antecedent mental disorders (M4), only three of the five GMCs previously associated with PEs (frequent or severe headache, other chronic pain, and asthma) remained statistically significant (OR = 1.5, 95% CI = 1.2-1.9; OR = 1.7, 95% CI = 1.2-2.4; OR = 1.6, 95% CI = 1.2-2.1 respectively).

When we repeated the main analyses using additional adjustment for smoking, there was no substantial change in the results except for other chronic lung diseases (as expected) in which the odds ratios attenuated substantially in both analyses (supplementary tables S3a & S3b). However, in the final adjusted models, the associations between PEs and other chronic lung diseases (whether PEs as the predictor for GMCs or vice versa) were not significant.

There was a significant dose-response relationship between the number of GMCs and subsequent first onset PEs, with ORs monotonically increasing with increasing number of GMCs ($\chi^2_4 = 117.9$, $P < .001$) indicating that multimorbidity of GMCs predicts first onset PEs (M2, Table 3). This model, however, assumes an additive relationship between the number of GMCs and onset of PEs. In the next models (M3 and M4) that take type of GMCs into account and remove the additive assumption about the effect of number of GMCs, the ORs for the association of GMCs with odds of subsequent PEs became progressively smaller with each additional GMC. These sub-additive interactions need to be interpreted with caution however as number-of-general medical conditions as a set fell short of significance.

Discussion

In this large, population-based dataset from 16 countries we found that temporally prior PEs were significantly associated with subsequent first onset of 8 of the 12 GMCs studied (i.e., arthritis, back or neck pain, other chronic pain, frequent or severe headache, heart disease, high blood pressure, diabetes, and peptic ulcer). PEs were not significantly associated with subsequent onset of asthma, cancer, other chronic lung disease or stroke. After adjustment for mental disorders antecedent to the GMCs, all previously significant associations remained significant, although all were somewhat attenuated which suggests that a portion of these PE-GMC associations are explained by comorbid mental disorders. These results extend findings from prior studies (Saha *et al.*, 2011a, Moreno *et al.*, 2013, Oh and DeVylder, 2015) by providing description of associations between PEs and a range of GMCs in the general population independent of comorbid mental disorders. In addition, our temporally ordered survival analyses based on a large cross-national sample provide new insights into the temporal direction of associations between PEs and GMCs. For while we found that prior onset PEs were predictive of 8 of the 12 GMCs, conversely, we also found that 3 of the 12 GMCs (i.e., frequent or severe headache, other chronic pain, and asthma) were significantly associated with subsequent first onset of PEs.

We were also able to undertake examination of how associations between PEs and GMCs varied by PE severity, as indicated by number of PE types and frequency of annualized PEs. For the associations of PEs with subsequent GMCs, we observed a dose-response pattern for many (although not all) of the associations whereby those with a higher number of PEs types and higher frequency of annualized PEs were more likely to develop subsequent GMCs. For many associations though, especially for those of PEs with subsequent pain conditions (with the exception of headache), this pattern was no longer evident after adjustment for mental disorders, suggesting that some of the increased risk of GMCs associated with a higher burden of prior PEs may be mediated by comorbid mental disorders. In considering the reverse direction of associations of GMCs with subsequent PEs, we similarly observed a dose response pattern whereby a higher count of temporally prior GMCs was associated with higher odds of subsequent first onset of PEs, although the added risk became smaller with each additional GMC. While it is widely accepted that people with psychotic disorders are more likely to develop a range of chronic GMCs (Stubbs *et al.*, 2016) and have reduced life expectancy (Laursen *et al.*, 2014, Hjorthoj *et al.*, 2017), our findings suggest that those with PEs, even in the absence of known psychotic disorders, also warrant close scrutiny in relation to physical health.

The observational nature of this study precludes any firm conclusions about whether these associations reflect causal mechanisms. That said, there are plausible mechanisms that could be involved. The fact that the strongest temporal sequence observed in this study was from prior PEs to subsequent onset of GMCs is consistent with the now substantial evidence for associations between antecedent common mental disorders and subsequent onset of GMCs (Thurston *et al.*, 2013, Whooley and Wong, 2013, Scott, 2014, Scott *et al.*, 2016). This raises the possibility that some of the same mechanisms that mediate the relationship between the common mental disorders and GMCs may be contributing to the associations between PEs and GMCs, and one such mechanism may be deleterious health behaviours associated with PEs such as smoking (Moreno *et al.*, 2013). However, when we repeated the main analysis controlling for smoking, there was no substantial change in the results indicating that the association between PEs and GMCs was not affected substantially by smoking history. It may also be relevant that PEs have a well-established relationship with sleep disturbance (Koyanagi and Stickley, 2015b, Thompson *et al.*, 2015, DeVylder and Kelleher, 2016, Oh *et al.*, 2016, Andorko *et al.*, 2017); poor sleep could therefore be part of a nexus of adverse health behaviours associated with PEs that mediates associations with poor health outcomes, but this requires further study before any conclusions can be drawn. To the extent that PEs serve as a marker

of general psychological distress (Yung *et al.*, 2006, Saha *et al.*, 2011c), it is also theoretically conceivable that PEs could be associated with subsequent GMCs via chronic elevation or dysregulation of the physiological stress response pathways given that considerable evidence has accrued for these biological mechanisms in the associations of depression and anxiety with subsequent cardio-metabolic conditions (Davies *et al.*, 2010, Stetler and Miller, 2011). However, this suggestion remains speculative in the absence of any known evidence for such biological perturbations in people with PEs; this is an important area for future research. In addition to these potential causal explanations, it should also be noted that there are also several potential shared determinants of PEs and GMCs such as genetics, low birth weight and adverse early circumstances, and indeed, sleep disturbances. On the basis of this study, therefore, we can say that PEs appear to be risk markers for a range of subsequent poor health outcomes, but determining whether they are causal risk factors will require more definitive study designs that can control for a range of potential confounds.

After adjustment for comorbid mental disorders, the only GMCs that were associated with subsequent onset of PEs were asthma and two of the pain-related conditions (frequent/severe headaches and other chronic pain). This suggests the possibility that inflammatory mechanisms related to GMCs could contribute to the subsequent emergence of PEs. For example, a birth cohort study reported an association between childhood asthma and/or eczema and the onset of PEs by age 13 years (Khandaker *et al.*, 2014). The fact that frequent/severe headaches and other chronic pain conditions were significantly associated with PEs in both temporal directions is interesting in light of the robust evidence from prior studies of the relationship between PEs and pain conditions (Koyanagi and Stickley, 2015a, 2016b). Of note is that while one of those prior studies (2016b) found that the significant association between PEs and pain was fully accounted for by depression and anxiety disorders, the present study found these associations between PEs and pain conditions (in both temporal directions) to persist despite comprehensive adjustment for 21 comorbid mental disorders. The well-established connections between chronic pain and sleep disturbance (Smith and Haythornthwaite, 2004), taken together with the several reports cited above of sleep disturbance in association with PEs, suggest that the present study's findings may reflect complex reciprocal relationships between chronic pain, sleep disturbance and psychological distress, particularly in the context of multimorbidity. It should also be noted that people with sleep disturbance may take hypnotic medications, which may influence the association between sleep disturbance and PEs – this topic warrants additional research.

While the current study has many strengths (e.g., range of PE types, large sample size, range of countries, uniform methodology for data collection), the methodological limitations are also considerable. Perhaps chief amongst these is the fact that the analyses were dependent on retrospective recall of the occurrence of mental disorders and PEs. Lifetime recall of mental disorders is unreliable and recall of the onset timing of mental disorders is known to be subject to bias (Simon and Von Korff, 1995, Moffitt *et al.*, 2010). Although the probing strategy employed in the WMH surveys has been shown to reduce this bias to some extent (Knäuper *et al.*, 1999), it is likely that some inaccuracy in onset timing remains and that mild disorders in particular will be under-recalled (Wells and Horwood, 2004). Recall of AOO of the GMCs is generally more reliable (Pattaro *et al.*, 2007), but the assessment of GMCs in this study was less rigorous than the assessment of mental health problems and self-report of physician-assigned diagnoses will miss some conditions that are asymptomatic in early stages. These limitations will undoubtedly have resulted in some individuals with a true history of PE, mental disorder and/or general medical condition being misclassified as non-cases. It is important to note though that this kind of misclassification tends to bias associations towards the null, making the results conservative. Survival bias may also contribute to the conservative nature of these findings. We excluded those who screened positive for possible psychotic disorders but it is possible that some respondents who reported PEs had an untreated psychotic disorder. Finally, it should be noted that many of the GMCs examined in this study are chronic conditions of aging (e.g., heart disease, arthritis, cancer, stroke). While the median age of onset for PEs is 26 years (McGrath *et al.*, 2016c), later-onset PEs have also been noted. It is feasible that the mechanisms underlying later-onset PEs may be influenced by the neurobiological correlates of these GMCs.

In summary, in this large community-based cross-sectional study, we found that individuals with prior onset of PEs were more likely to self-report subsequent development or diagnosis of a wide range of general medical conditions (i.e., arthritis, back or neck pain, other chronic pain, frequent or severe headache, heart disease, high blood pressure, diabetes, and peptic ulcer) independent of comorbid mental disorders. A higher burden of PEs was associated with higher odds of subsequent GMC onset. In addition, 3 of the 12 GMCs studied (i.e., other chronic pain, frequent or severe headache, asthma) were significantly associated with subsequent onset of PEs. Although the temporal directions of the associations observed here will need to be confirmed in prospective designs, this study contributes substantial evidence in support of the proposition that PEs are associated with GMCs even after controlling for mental disorder comorbidity. It remains to be determined whether these associations are causal, but there are several plausible causal mechanisms. Behavioural and biological mechanisms that could mediate these associations between

PEs and physical morbidity are an important area for future research. Clinicians should be aware that psychotic symptoms, independent of comorbid psychotic or other mental disorder, may be risk markers for a range of adverse health outcomes.

ACKNOWLEDGEMENTS AND FUNDING

The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the United States National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the United States Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical Inc., GlaxoSmithKline, and Bristol-Myers Squibb. We thank the staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in the design, analysis, interpretation of results, or preparation of this paper. The views and opinions expressed in this report are those of the authors and should not be construed to represent the views of the World Health Organization, other sponsoring organizations, agencies, or governments.

The Argentina survey -- Estudio Argentino de Epidemiología en Salud Mental (EASM) -- was supported by a grant from the Argentinian Ministry of Health (Ministerio de Salud de la Nación). The Colombian National Study of Mental Health (NSMH) is supported by the Ministry of Social Protection. The ESEMeD surveys were funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308), the Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Mexican National Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of Health, Alcohol Advisory Council, and the Health Research Council. The Peruvian World Mental Health Study was funded by the National Institute of Health of the Ministry of Health of Peru. The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology (FCT) and Ministry of Health. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health, present National School of Public Health Management & Professional Development, Bucharest), with technical support of Metro Media Transilvania, the National Institute of Statistics – National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania

SRL. The US National Comorbidity Survey Replication (NCS-R) is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. Dr McGrath received John Cade Fellowship APP1056929 from the National Health and Medical Research Council and Niels Bohr Professorship from the Danish National Research Foundation.

A complete list of all within-country and cross-national WMH publications can be found at http://www.hcp.med.harvard.edu/wmh/.

CONFLICT OF INTEREST

Competing interests: In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; was a consultant for Johnson & Johnson Wellness and Prevention, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare research.

ROLE OF THE FUNDER/SPONSOR

The funders had no role in the design and 15 conduct of the study; collection, management, analysis, and interpretation of 16 the data; preparation, review, or approval of the manuscript; and decision to 17 submit the manuscript for publication.

ACKNOWLEDGE WMH COLLABORATORS

The WHO World Mental Health Survey collaborators are Sergio Aguilar-Gaxiola, MD, PhD, Ali Al-Hamzawi, MD, Mohammed Salih Al-Kaisy, MD, Jordi Alonso, MD, PhD, Laura Helena Andrade, MD, PhD, Corina Benjet, PhD, Guilherme Borges,ScD, Evelyn J. Bromet, PhD, Ronny Bruffaerts, PhD, Brendan Bunting, PhD, Jose Miguel Caldas de Almeida, MD, PhD, Graca Cardoso, MD, PhD, Somnath Chatterji, MD, Alfredo H. Cia, MD, Louisa Degenhardt, PhD, Koen Demyttenaere, MD, PhD, John Fayyad, MD, Silvia Florescu, MD, PhD, Giovanni de Girolamo, MD, Oye Gureje, MD, DSc, FRCPsych, Josep Maria Haro, MD, PhD, Yanling He, MD, Hristo Hinkov, MD, PhD, Chi-yi Hu, MD, PhD, Yueqin Huang, MD, MPH, PhD, Peter de Jonge, PhD, Aimee Nasser Karam, PhD, Elie G. Karam, MD, Norito Kawakami, MD, DMSc, Ronald C. Kessler, PhD, Andrzej Kiejna, MD, PhD, Viviane Kovess-Masfety, MD, PhD, Sing Lee, MB,BS, Jean-Pierre Lepine, MD, Daphna Levinson, PhD, John McGrath, MD, PhD, Maria Elena Medina-Mora, PhD, Jacek Moskalewicz, PhD, Fernando Navarro-Mateu, MD, PhD, Beth-Ellen Pennell, MA, Marina Piazza, MPH, ScD, Jose Posada-Villa, MD, Kate M. Scott, PhD, Tim Slade, PhD, Juan Carlos Stagnaro, MD, PhD, Dan J. Stein, FRCPC, PhD, Margreet ten Have, PhD, Yolanda Torres, MPH, Dra.HC, Maria Carmen Viana, MD, PhD, Harvey Whiteford, MBBS, PhD, David R. Williams, MPH, PhD, Bogdan Wojtyniak, ScD.

REFERENCES

Andorko, N. D., Mittal, V., Thompson, E., Denenny, D., Epstein, G., Demro, C., Wilson, C., Sun, S., Klingaman, E. A., DeVylder, J., Oh, H., Postolache, T. T., Reeves, G. M. & Schiffman, J. (2017). The association between sleep dysfunction and psychosis-like experiences among college students. *Psychiatry Research* **248**, 6-12.

Baumeister, H., Kriston, L., Bengel, J. & Harter, M. (2010). High agreement of self-report and physician-diagnosed somatic conditions yields limited bias in examining mental-physical comorbidity. *Journal of Clinical Epidemiology* **63**, 558-65.

Davies, S. J., Esler, M. & Nutt, D. J. (2010). Anxiety--bridging the heart/mind divide. *J Psychopharmacol* **24**, 633-8.

DeVylder, J. E., Burnette, D. & Yang, L. H. (2014). Co-occurrence of psychotic experiences and common mental health conditions across four racially and ethnically diverse population samples. *Psychological Medicine* **44**, 3503-13.

DeVylder, J. E. & Kelleher, I. (2016). Clinical significance of psychotic experiences in the context of sleep disturbance or substance use. *Psychological Medicine* **46**, 1761-7.

Doll, R. (1998). Uncovering the effects of smoking: historical perspective. *Statistical Methods in Medical Research* **7**, 87-117.

Freeman, D., Sheaves, B., Goodwin, G. M., Yu, L. M., Nickless, A., Harrison, P. J., Emsley, R., Luik, A. I., Foster, R. G., Wadekar, V., Hinds, C., Gumley, A., Jones, R., Lightman, S., Jones, S., Bentall, R., Kinderman, P., Rowse, G., Brugha, T., Blagrove, M., Gregory, A. M., Fleming, L., Walklet, E., Glazebrook, C., Davies, E. B., Hollis, C., Haddock, G., John, B., Coulson, M., Fowler, D., Pugh, K., Cape, J., Moseley, P., Brown, G., Hughes, C., Obonsawin, M., Coker, S., Watkins, E., Schwannauer, M., MacMahon, K., Siriwardena, A. N. & Espie, C. A. (2017). The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis. *Lancet Psychiatry*.

Haro, J. M., Arbabzadeh-Bouchez, S., Brugha, T. S., de Girolamo, G., Guyer, M. E., Jin, R., Lepine, J. P., Mazzi, F., Reneses, B., Vilagut, G., Sampson, N. A. & Kessler, R. C. (2006). Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. *International Journal of Methods in Psychiatric Research* **15**, 167-80.

Hjorthoj, C., Sturup, A. E., McGrath, J. J. & Nordentoft, M. (2017). Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* **4**, 295-301.

Kessler, R. C., Haro, J. M., Heeringa, S. G., Pennell, B. E. & Ustun, T. B. (2006). The World Health Organization World Mental Health Survey Initiative. *Epidemiologia e Psichiatria Sociale* **15**, 161-6.

Kessler, R. C. & Üstün, T. B. (2004). The World Mental Health (WMH) Survey Initiative Version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). *International Journal of Methods in Psychiatric Research* **13**, 93-121.

Kessler, R. C. & Üstün, T. B. (2008). The World Health Organization Composite International Diagnostic Interview. In *The WHO World Mental Health Surveys: Global Perspectives on the Epidemiology of Mental Disorders* (ed. R. C. Kessler and T. B. Üstün), pp. 58-90. Cambridge University Press: New York.

Keto, J., Ventola, H., Jokelainen, J., Linden, K., Keinanen-Kiukaanniemi, S., Timonen, M., Ylisaukko-Oja, T. & Auvinen, J. (2016). Cardiovascular disease risk factors in relation to smoking behaviour and history: a population-based cohort study. *Open Heart* **3**, e000358.

Khandaker, G. M., Zammit, S., Lewis, G. & Jones, P. B. (2014). A population-based study of atopic disorders and inflammatory markers in childhood before psychotic experiences in adolescence. *Schizophrenia Research* **152**, 139-145.

Knäuper, B., Cannell, C. F., Schwarz, N., Bruce, M. L. & Kessler, R. C. (1999). Improving accuracy of major depression age-of-onset reports in the US National Comorbidity Survey. *International Journal of Methods in Psychiatric Research* **8**, 39-48.
Koyanagi, A., Oh, H., Stubbs, B., Haro, J. M. & DeVylder, J. E. (2017). Epidemiology of depression with psychotic experiences and its association with chronic physical conditions in 47 low- and middle-income countries. *Psychological Medicine* **47**, 531-542.
Koyanagi, A. & Stickley, A. (2015a). The association between psychosis and severe pain in community-dwelling adults: Findings from 44 low- and middle-income countries. *Journal of Psychiatric Research* **69**, 19-26.
Koyanagi, A. & Stickley, A. (2015b). The Association between Sleep Problems and Psychotic Symptoms in the General Population: A Global Perspective. *Sleep* **38**, 1875-85.
Koyanagi, A., Stickley, A. & Haro, J. M. (2016a). Psychotic symptoms and smoking in 44 countries. *Acta Psychiatrica Scandinavica* **133**, 497-505.
Koyanagi, A., Stickley, A. & Haro, J. M. (2016b). Subclinical psychosis and pain in an English national sample: The role of common mental disorders. *Schizophrenia Research* **175**, 209-15.
Laursen, T. M., Nordentoft, M. & Mortensen, P. B. (2014). Excess early mortality in schizophrenia. *Annual Review of Clinical Psychology* **10**, 425-48.
Lawrence, D., Hancock, K. J. & Kisely, S. (2013). The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. *BMJ* **346**, f2539.
Linscott, R. J. & van Os, J. (2013). An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: on the pathway from proneness to persistence to dimensional expression across mental disorders. *Psychological Medicine* **43**, 1133-49.
McGrath, J. J., Alati, R., Clavarino, A., Williams, G. M., Bor, W., Najman, J. M., Connell, M. & Scott, J. G. (2016a). Age at first tobacco use and risk of subsequent psychosis-related outcomes: A birth cohort study. *Australian and New Zealand Journal of Psychiatry* **50**, 577-83.
McGrath, J. J., McLaughlin, K. A., Saha, S., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Bruffaerts, R., de Girolamo, G., de Jonge, P., Esan, O., Florescu, S., Gureje, O., Haro, J. M., Hu, C., Karam, E. G., Kovess-Masfety, V., Lee, S., Lepine, J. P., Lim, C. C., Medina-Mora, M. E., Mneimneh, Z., Pennell, B. E., Piazza, M., Posada-Villa, J., Sampson, N., Viana, M. C., Xavier, M., Bromet, E. J., Kendler, K. S. & Kessler, R. C. (2017). The association between childhood adversities and subsequent first onset of psychotic experiences: a cross-national analysis of 23 998 respondents from 17 countries. *Psychological Medicine* **47**, 1230-1245.
McGrath, J. J., Saha, S., Al-Hamzawi, A., Alonso, J., Bromet, E. J., Bruffaerts, R., Caldas-de-Almeida, J. M., Chiu, W. T., de Jonge, P., Fayyad, J., Florescu, S., Gureje, O., Haro, J. M., Hu, C., Kovess-Masfety, V., Lepine, J. P., Lim, C. C., Mora, M. E., Navarro-Mateu, F., Ochoa, S., Sampson, N., Scott, K., Viana, M. C. & Kessler, R. C. (2015). Psychotic Experiences in the General Population: A Cross-National Analysis Based on 31261 Respondents From 18 Countries. *JAMA Psychiatry* **72**, 697-705.
McGrath, J. J., Saha, S., Al-Hamzawi, A., Andrade, L., Benjet, C., Bromet, E. J., Browne, M. O., Caldas de Almeida, J. M., Chiu, W. T., Demyttenaere, K., Fayyad, J., Florescu, S., de Girolamo, G., Gureje, O., Haro, J. M., Ten Have, M., Hu, C., Kovess-Masfety, V., Lim, C. C., Navarro-Mateu, F., Sampson, N., Posada-Villa, J., Kendler, K. S. & Kessler, R. C. (2016b). The Bidirectional Associations Between Psychotic Experiences and DSM-IV Mental Disorders. *American Journal of Psychiatry* **173**, 997-1006.
McGrath, J. J., Saha, S., Al-Hamzawi, A. O., Alonso, J., Andrade, L., Borges, G., Bromet, E. J., Oakley Browne, M., Bruffaerts, R., Caldas de Almeida, J. M., Fayyad, J., Florescu, S., de Girolamo, G., Gureje, O., Hu, C., de Jonge, P., Kovess-Masfety, V., Lepine, J. P., Lim, C. C., Navarro-Mateu, F., Piazza, M., Sampson, N., Posada-Villa, J., Kendler, K. S. & Kessler, R. C. (2016c). Age of Onset and Lifetime Projected Risk of Psychotic Experiences: Cross-National Data From the World Mental Health Survey. *Schizophrenia Bulletin* **42**, 933-41.

Moffitt, T., Caspi, A., Taylor, A., Kokaua, J., Milne, B., Polanczyk, G. & Poulton, R. (2010). How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. *Psychological medicine* **40**, 899.
Moreno, C., Nuevo, R., Chatterji, S., Verdes, E., Arango, C. & Ayuso-Mateos, J. L. (2013). Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. *World Psychiatry* **12**, 251-7.
Oh, H. & DeVylder, J. (2015). Psychotic symptoms predict health outcomes even after adjusting for substance use, smoking and co-occurring psychiatric disorders: findings from the NCS-R and NLAAS. *World Psychiatry* **14**, 101-2.
Oh, H. Y., Singh, F., Koyanagi, A., Jameson, N., Schiffman, J. & DeVylder, J. (2016). Sleep disturbances are associated with psychotic experiences: Findings from the National Comorbidity Survey Replication. *Schizophrenia Research* **171**, 74-8.
Pattaro, C., Locatelli, F., Sunyer, J. & de Marco, R. (2007). Using the age at onset may increase the reliability of longitudinal asthma assessment. *Journal of Clinical Epidemiology* **60**, 704-711.
RTI International (1999). SUDAAN: Software for the statistical analysis of correlated data [computer program]. . RTI International: Research Triangle Park, North Carolina, USA.
Saha, S., Scott, J., Varghese, D. & McGrath, J. (2011a). The association between physical health and delusional-like experiences: a general population study. *PloS One* **6**, e18566.
Saha, S., Scott, J. G., Johnston, A. K., Slade, T. N., Varghese, D., Carter, G. L. & McGrath, J. J. (2011b). The association between delusional-like experiences and suicidal thoughts and behaviour. *Schizophrenia Research* **132**, 197-202.
Saha, S., Scott, J. G., Varghese, D. & McGrath, J. J. (2011c). The association between general psychological distress and delusional-like experiences: a large population-based study. *Schizophrenia Research* **127**, 246-51.
Scott, K. M. (2014). Depression, anxiety and incident cardiometabolic diseases. *Curr Opin Psychiatry* **27**, 289-93.
Scott, K. M., Lim, C., Al-Hamzawi, A., Alonso, J., Bruffaerts, R., Caldas-de-Almeida, J. M., Florescu, S., de Girolamo, G., Hu, C., de Jonge, P., Kawakami, N., Medina-Mora, M. E., Moskalewicz, J., Navarro-Mateu, F., O'Neill, S., Piazza, M., Posada-Villa, J., Torres, Y. & Kessler, R. C. (2016). Association of Mental Disorders With Subsequent Chronic Physical Conditions: World Mental Health Surveys From 17 Countries. *JAMA Psychiatry* **73**, 150-8.
Sharifi, V., Eaton, W. W., Wu, L. T., Roth, K. B., Burchett, B. M. & Mojtabai, R. (2015). Psychotic experiences and risk of death in the general population: 24-27 year follow-up of the Epidemiologic Catchment Area study. *British Journal of Psychiatry* **207**, 30-6.
Simon, G. & Von Korff, M. (1995). Recall of psychiatric history in cross-sectional surveys: implications for epidemiologic research. *Epidemiological Reviews* **17**, 221-227.
Smith, M. T. & Haythornthwaite, J. A. (2004). How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. *Sleep Medicine Reviews* **8**, 119-32.
Stetler, C. & Miller, G. E. (2011). Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. *Psychosomatic Medicine* **73**, 114-26.
Stubbs, B., Koyanagi, A., Veronese, N., Vancampfort, D., Solmi, M., Gaughran, F., Carvalho, A. F., Lally, J., Mitchell, A. J., Mugisha, J. & Correll, C. U. (2016). Physical multimorbidity and psychosis: comprehensive cross sectional analysis including 242,952 people across 48 low- and middle-income countries. *BMC Medicine* **14**, 189.
Thompson, A., Lereya, S. T., Lewis, G., Zammit, S., Fisher, H. L. & Wolke, D. (2015). Childhood sleep disturbance and risk of psychotic experiences at 18: UK birth cohort. *British Journal of Psychiatry* **207**, 23-9.
Thurston, R. C., Rewak, M. & Kubzansky, L. D. (2013). An anxious heart: anxiety and the onset of cardiovascular diseases. *Progress in Cardiovascular Diseases* **55**, 524-37.

Wells, J. E. & Horwood, L. J. (2004). How accurate is recall of key symptoms of depression?: a comparison of recall and longitudinal reports. *Psychological medicine* **34**, 1001-11.
Whooley, M. A. & Wong, J. M. (2013). Depression and cardiovascular disorders. *Annual Review of Clinical Psychology* **9**, 327-54.
Yung, A. R., Buckby, J. A., Cotton, S. M., Cosgrave, E. M., Killackey, E. J., Stanford, C., Godfrey, K. & McGorry, P. D. (2006). Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. *Schizophrenia Bulletin* **32**, 352-9.

Table 1. Prevalence of general medical conditions (GMC) among respondents with and without lifetime psychotic experiences (PEs) (n = 28,002)

General medical conditions	Total Sample			Respondents without lifetime PEs			Respondents with lifetime PEs			Respondents endorsing both lifetime GMC and PE									
										PEs prior to GMC onset			GMC in the same year as PEs onset			GMC prior to PEs onset			Goodness-of-fit test for equal proportion[a]	
	n	%[b]	SE	n	%[b]	SE	n	%[b]	SE	n	%[b]	SE	n	%[b]	SE	n	%[b]	SE	χ^2_1	p-value
Arthritis	5640	18·1	0·4	5132	17·7	0·4	508	26·1	1·4	308	61·0	3·6	22	4·2	1·3	178	34·9	3·4	22·5*	<·0001
Back or neck pain	7839	24·3	0·4	7043	23·6	0·4	796	38·3	1·7	439	55·7	2·9	32	4·1	1·1	325	40·2	2·7	14·8*	0·0001
Frequent or severe headaches	6701	19·3	0·4	5958	18·5	0·4	743	34·1	1·5	324	43·9	2·6	55	7·0	1·3	364	49·1	2·7	2·1	0·1475
Other chronic pain	2527	7·1	0·2	2152	6·6	0·2	375	17·0	1·3	213	57·8	4·0	12	4·0	1·4	150	38·2	3·9	11·1*	0·0008
Heart disease	1949	6·3	0·2	1791	6·2	0·2	158	9·1	1·1	103	72·6	5·4	7	5·9	2·2	48	21·5	5·2	32·0*	<·0001
High blood pressure	4808	15·4	0·3	4372	15·1	0·3	436	21·2	1·4	306	69·3	3·2	21	4·2	1·1	109	26·6	3·1	201·8*	<·0001
Asthma	2397	7·8	0·2	2103	7·5	0·2	294	15·0	1·3	105	31·3	3·9	15	4·6	1·6	174	64·2	4·1	68·8*	<·0001
Diabetes	1463	4·6	0·2	1331	4·5	0·2	132	6·1	0·8	97	80·8	4·3	4	2·4	1·6	31	16·8	4·0	-[c]	-[c]
Peptic ulcer	1826	5·5	0·2	1622	5·3	0·2	204	9·5	0·9	123	62·6	4·9	8	2·1	0·8	73	35·3	4·8	60·2*	<·0001
Cancer	868	2·9	0·1	759	2·8	0·1	109	4·5	0·5	75	68·2	5·9	4	3·0	1·8	30	28·8	5·8	91·6*	<·0001
Other chronic lung diseases	435	1·3	0·1	387	1·3	0·1	48	2·0	0·6	32	73·8	9·6	2	3·6	2·8	14	22·6	9·0	13·4*	0·0003
Stroke	467	2·0	0·1	415	1·9	0·1	52	2·5	0·5	39	77·1	7·6	4	6·9	4·4	9	16·0	6·4	110·5*	<·0001

SE, standard error

*Significant at the ·05 level, 2-sided test.

[a]Chi square tests comparing the proportion of respondents with PE onset prior to GMC onset versus the proportion of respondents with GMC onset prior to PE onset.

[b]Estimates are based on weighted data.

[c]Unstable estimates due to small design effect.

Table 2. Associations between temporally prior psychotic experiences (PEs) and the subsequent onset of general medical conditions (GMCs)

Type of GMCs	Any PE		Number of PE types								PE Frequency metric	
			Exactly 1 PE type		Exactly 2 PE types		3 or more PE types		Joint significance of the 3 number-of-PE type measures		> 0·3 episodes/year	
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	χ^2_3	[p-value]	OR	(95% CI)
I. No adjustment for antecedent mental disorders[a]												
Arthritis	1·8*	(1·5-2·1)	1·6*	(1·3-2·0)	2·2*	(1·5-3·1)	2·3*	(1·4-3·8)	$\chi^2_3 = 55·3$*	P <·001	1·8*	(1·3-2·4)
Back or neck pain	1·8*	(1·5-2·1)	1·7*	(1·4-2·0)	2·0*	(1·4-2·9)	2·3*	(1·5-3·7)	$\chi^2_3 = 55·7$*	P <·001	2·0*	(1·6-2·5)
Frequent or severe headaches	1·7*	(1·5-2·0)	1·6*	(1·3-2·0)	1·7*	(1·2-2·5)	3·2*	(2·1-4·8)	$\chi^2_3 = 73·3$*	P <·001	2·3*	(1·8-3·0)
Other chronic pain	2·3*	(1·8-3·0)	2·2*	(1·7-2·8)	3·1*	(1·8-5·2)	2·2*	(1·2-3·9)	$\chi^2_3 = 49·1$*	P <·001	2·3*	(1·7-3·1)
Heart disease	1·9*	(1·4-2·5)	1·7*	(1·2-2·4)	2·3*	(1·4-3·6)	3·2*	(1·1-9·6)	$\chi^2_3 = 25·5$*	P <·001	2·2*	(1·4-3·5)
High blood pressure	1·4*	(1·2-1·7)	1·3*	(1·0-1·6)	1·8*	(1·1-2·9)	1·9	(1·0-3·8)	$\chi^2_3 = 14·5$*	P = 0·002	1·6*	(1·2-2·1)
Asthma	1·3	(1·0-1·7)	1·2	(0·9-1·7)	1·7*	(1·0-2·8)	1·2	(0·5-2·5)	$\chi^2_3 = 5·3$	P = 0·150	1·8*	(1·2-2·8)
Diabetes	1·7*	(1·2-2·3)	1·9*	(1·3-2·7)	1·1	(0·6-2·2)	0·9	(0·4-2·5)	$\chi^2_3 = 12·8$*	P = 0·005	2·3*	(1·4-3·8)
Peptic ulcer	1·9*	(1·5-2·5)	1·8*	(1·3-2·5)	1·5	(0·9-2·6)	6·2*	(2·8-13·6)	$\chi^2_3 = 33·4$*	P <·001	2·1*	(1·3-3·2)
Cancer	1·2	(0·8-1·6)	1·1	(0·8-1·6)	1·1	(0·5-2·5)	1·8	(0·7-4·6)	$\chi^2_3 = 2·4$	P = 0·499	1·4	(0·9-2·3)
Other chronic lung diseases	1·8	(0·8-3·7)	1·0	(0·5-1·8)	4·7*	(1·4-15·7)	3·2*	(1·2-8·8)	$\chi^2_3 = 10·5$*	P = 0·015	1·4	(0·6-3·2)
Stroke	1·4	(0·9-2·3)	1·4	(0·8-2·4)	2·0	(0·7-5·6)	-[c]	-[c]	-[c]	-[c]	1·8	(0·7-4·4)
II. Adjusted for antecedent mental disorders[b]												
Arthritis	1·5*	(1·3-1·8)	1·5*	(1·2-1·8)	1·8*	(1·4-2·4)	1·6	(0·9-3·0)	$\chi^2_3 = 36·8$*	P <·001	1·5*	(1·1-2·0)
Back or neck pain	1·5*	(1·3-1·8)	1·5*	(1·3-1·8)	1·7*	(1·3-2·3)	1·5	(0·9-2·5)	$\chi^2_3 = 32·6$*	P <·001	1·7*	(1·3-2·1)
Frequent or severe headaches	1·5*	(1·3-1·7)	1·4*	(1·2-1·8)	1·4*	(1·0-1·9)	2·0*	(1·3-3·1)	$\chi^2_3 = 28·9$*	P <·001	1·8*	(1·4-2·4)
Other chronic pain	1·9*	(1·4-2·4)	1·8*	(1·4-2·4)	2·3*	(1·3-3·9)	1·1	(0·5-2·2)	$\chi^2_3 = 25·8$*	P <·001	1·8*	(1·3-2·4)
Heart disease	1·7*	(1·3-2·3)	1·6*	(1·1-2·2)	1·9*	(1·1-3·2)	2·7	(0·9-7·9)	$\chi^2_3 = 14·1$*	P = 0·003	2·0*	(1·2-3·1)
High blood pressure	1·3*	(1·1-1·5)	1·2	(1·0-1·4)	1·5	(1·0-2·4)	1·5	(0·8-2·9)	$\chi^2_3 = 7·5$	P = 0·058	1·4*	(1·1-1·8)
Asthma	1·2	(0·9-1·6)	1·1	(0·8-1·6)	1·5	(0·9-2·4)	0·9	(0·4-2·1)	$\chi^2_3 = 3·0$	P = 0·395	1·6*	(1·1-2·5)
Diabetes	1·6*	(1·1-2·2)	1·8*	(1·2-2·6)	1·0	(0·5-2·0)	0·8	(0·3-2·1)	$\chi^2_3 = 10·4$*	P = 0·015	2·1*	(1·2-3·5)
Peptic ulcer	1·6*	(1·2-2·1)	1·5*	(1·1-2·1)	1·2	(0·7-2·0)	4·1*	(1·7-9·9)	$\chi^2_3 = 14·4$*	P = 0·002	1·7*	(1·1-2·7)
Cancer	1·1	(0·8-1·5)	1·1	(0·7-1·5)	1·0	(0·5-2·2)	1·4	(0·6-3·7)	$\chi^2_3 = 0·6$	P = 0·887	1·3	(0·8-2·1)
Other chronic lung diseases	1·4	(0·6-3·1)	0·8	(0·5-1·5)	3·3	(0·8-14·0)	2·2	(0·8-5·9)	$\chi^2_3 = 5·0$	P = 0·174	1·1	(0·5-2·3)
Stroke	1·2	(0·7-2·0)	1·2	(0·7-2·1)	1·7	(0·6-4·7)	-[c]	-[c]	-[c]	-[c]	1·6	(0·6-4·2)

OR, odds ratio; CI, Confidence interval

*Significant at the ·05 level, 2-sided test.

[a]PE (any PE, number of PE types, and PE frequency metric) was used as a predictor of general medical condition outcomes in separate discrete-time survival models. These models control for age at interview, sex, person-year, and country.

[b]These models additionally control for 21 antecedent mental disorders. See supplementary table S2c for the list of mental disorders.

[c]Unstable estimates due to small cell counts.

Table 3. Associations between temporally prior general medical conditions (GMCs) and the subsequent onset of psychotic experiences (PEs)

	Base model[a]		Multivariate model (M1)[b]		Multivariate model (M2)[c]		Multivariate model (M3)[d]		Multivariate model (M4)[e]	
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)
I. Type of GMCs										
Arthritis	1·9*	(1·5-2·5)	1·4*	(1·1-1·9)	-	-	1·4*	(1·0-2·0)	1·4	(1·0-2·0)
Back or neck pain	1·9*	(1·5-2·4)	1·4*	(1·1-1·8)	-	-	1·4*	(1·0-1·9)	1·3	(1·0-1·8)
Frequent or severe headaches	2·1*	(1·7-2·5)	1·7*	(1·4-2·1)	-	-	1·7*	(1·4-2·2)	1·5*	(1·2-1·9)
Other chronic pain	2·7*	(2·1-3·5)	2·0*	(1·5-2·6)	-	-	2·0*	(1·4-2·8)	1·7*	(1·2-2·4)
Heart disease	1·5	(0·9-2·4)	1·0	(0·6-1·7)	-	-	1·1	(0·6-1·8)	1·0	(0·6-1·7)
High blood pressure	1·7*	(1·2-2·3)	1·3	(0·9-1·8)	-	-	1·4	(0·9-1·9)	1·3	(0·9-1·8)
Asthma	1·8*	(1·4-2·4)	1·7*	(1·3-2·2)	-	-	1·7*	(1·2-2·3)	1·6*	(1·2-2·1)
Diabetes	1·1	(0·7-1·9)	0·9	(0·5-1·5)	-	-	0·9	(0·5-1·5)	0·9	(0·5-1·5)
Peptic ulcer	1·7*	(1·2-2·5)	1·3	(0·9-1·9)	-	-	1·3	(0·9-2·0)	1·2	(0·8-1·8)
Cancer	1·6	(0·9-2·7)	1·3	(0·7-2·1)	-	-	1·3	(0·8-2·3)	1·2	(0·7-2·1)
Other chronic lung diseases	0·9	(0·4-2·0)	0·6	(0·3-1·3)	-	-	0·6	(0·3-1·3)	0·6	(0·3-1·2)
Stroke	1·2	(0·5-2·7)	0·8	(0·4-1·8)	-	-	0·9	(0·4-1·8)	0·9	(0·4-1·9)
Joint significance of all GMCs, χ^2_{12} [p - value]		N/A	$\chi^2_{12} = 175{\cdot}0$*, p < ·001			N/A	$\chi^2_{12} = 41{\cdot}4$*, p < ·001		$\chi^2_{12} = 26{\cdot}7$*, p = 0·009	
Difference between GMCs, χ^2_{11} [p - value]		N/A	$\chi^2_{11} = 27{\cdot}0$*, p = 0·005			N/A	$\chi^2_{11} = 23{\cdot}9$*, p = 0·013		$\chi^2_{11} = 17{\cdot}4$, p = 0·097	
II. Number of GMCs										
Exactly 1 GMC	-	-	-	-	1·6*	(1·3-2·0)	-	-	-	-
Exactly 2 GMCs	-	-	-	-	3·0*	(2·3-3·9)	1·3	(0·9-1·9)	1·3	(0·9-1·9)
Exactly 3 GMCs	-	-	-	-	3·2*	(2·3-4·5)	0·9	(0·5-1·7)	0·9	(0·5-1·6)
4 or more GMCs	-	-	-	-	4·4*	(3·2-6·1)	0·8	(0·3-1·9)	0·8	(0·3-1·8)
Joint significance of number-of-GMCs, χ^2_4 [p - value]		N/A		N/A	$\chi^2_4 = 117{\cdot}9$*, p < ·001		$\chi^2_4 = 6{\cdot}4$, p = 0·094		$\chi^2_4 = 6{\cdot}5$, p = 0·089	

OR, odds ratio; CI, Confidence interval

*Significant at the ·05 level, 2-sided test.

[a]Each model was estimated with one GMC entered at a time as predictor of PE onset controlling for age at interview, sex, person-year, and country.

[b]M1: Model was estimated with dummy variables for all GMC entered simultaneously as predictors of PE onset including the controls specified in (a).

[c]M2: Model was estimated with dummy variables for all number of GMC without any information about type entered simultaneously as predictors of PE onset including the controls specified in (a).

[d] M3: Model was estimated with dummy variables for type and number of GMC (exactly 2 GMCs,.., 4 or more GMCs) entered simultaneously as predictors of PE onset including the controls specified in (a).

[e]M4: Model was estimated with dummy variables for type and number of GMC (exactly 2 GMCs,.., 4 or more GMCs) entered simultaneously as predictors of PE onset including the controls specified in (a) and 21 antecedent mental disorders.

Supplementary table S1. World Mental Health (WMH) sample characteristics by World Bank income categories, and sample for psychotic experiences (PEs)

Country by income category	Survey[a]	Sample characteristics	Field dates	Age range	Sample size		Response rate (%)[b]
					Part I	PEs sample	
Low/ lower-middle-income countries							
Colombia	NSMH	All urban areas of the country	2003	18-65	4426	722	87·7
Iraq	IMHS	Nationally representative	2006-7	18-96	4332	4329	95·2
Peru	EMSMP	5 urban areas (approximately 38% of the total national population)	2004-5	18-65	3930	530	90·2
PRC[c] - Shenzhen[d]	Shenzhen	Shenzhen metropolitan area	2006-7	18-88	7132	2468	80·0
Upper-middle-income countries							
Mexico	M-NCS	All urban areas of the country	2001-2	18-65	5782	715	76·6
Romania	RMHS	Nationally representative	2005-6	18-96	2357	2357	70·9
High-income countries							
Argentina	AMHES	Nationally representative	2015	18-98	3927	2109	77·3
Belgium	ESEMeD	Nationally representative	2001-2	18-95	2419	319	50·6
France	ESEMeD	Nationally representative	2001-2	18-97	2894	301	45·9
Germany	ESEMeD	Nationally representative	2002-3	18-95	3555	408	57·8
Italy	ESEMeD	Nationally representative	2001-2	18-100	4712	617	71·3
New Zealand[d]	NZMHS	Nationally representative	2003-4	18-98	12790	7263	73·3
Portugal	NMHS	Nationally representative	2008-9	18-81	3849	2053	57·3
Spain	ESEMeD	Nationally representative	2001-2	18-98	5473	1159	78·6
The Netherlands	ESEMeD	Nationally representative	2002-3	18-95	2372	348	56·4
The United States	NCS-R	Nationally representative	2002-3	18-99	9282	2304	70·9
All countries combined					**79232**	**28002**	**71·3**

[a] **NSMH** (The Colombian National Study of Mental Health); **IMHS** (Iraq Mental Health Survey); **EMSMP** (La Encuesta Mundial de Salud Mental en el Peru); **M-NCS** (The Mexico National Comorbidity Survey); **RMHS** (Romania Mental Health Survey); **AMHES** (Argentina Mental Health Epidemiologic Survey; **ESEMeD** (The European Study Of The Epidemiology Of Mental Disorders); **NZMHS** (New Zealand Mental Health Survey); **NMHS** (Portugal National Mental Health Survey); **NCS-R** (The US National Comorbidity Survey Replication).

[b] The response rate is calculated as the ratio of the number of households in which an interview was completed to the number of households originally sampled, excluding from the denominator households known not to be eligible either because of being vacant at the time of initial contact or because the residents were unable to speak the designated languages of the survey. The weighted average response rate is 71·3%.

[c] People's Republic of China.

[d] For the purposes of cross-national comparisons we limit the sample to those 18+.

Supplementary table S2a. Six CIDI Psychotic experiences types in six European (ESEMed[a]) sites (Belgium, France, Germany, Italy, Netherlands, Spain)

Item	Type	Description
A. Saw a vision	**1**	Did you ever see something that wasn't really there that other people could not see? Please do not include any times when you were dreaming or half-asleep or under the influence of alcohol or drugs.
B. Heard voices	**2**	Did you ever hear things that other people said did not exist, like strange voices coming from inside your head talking to you or about you, or voices coming out of the air when there was no one around. Please do not include any times when you were dreaming or half-asleep or under the influence of alcohol or drugs.
C. Thought insertion	**3**	Did you ever believe that some mysterious force was inserting many different strange thoughts -- that were definitely not your own thoughts – directly into your head by means of x-rays or laser beams or other methods?
D. Mind control/passivity	**4**	Did you ever feel that your mind had been taken over by strange forces with laser beams or other methods that were making you do things you did not choose to do. Again, do not include times when you were dreaming or under the influence of alcohol or drugs.
E. Ideas of reference	**5**	Did you ever believe that some strange force was trying to communicate directly with you by sending special signs or signals that you could understand but that no one else could understand. Sometimes this happens by special signs coming through the radio or television.
F. Plot to harm/follow	**6**	Did you ever believe that there was an unjust plot going on to harm you or to have people follow you that your family and friends did not believe existed?

[a] ESEMeD = European Study of the Epidemiology of Mental Disorders

Supplementary table S2b. Six CIDI Psychotic experiences types in 10 non-ESEMed sites (People's Republic of China, Colombia, Mexico, Iraq, Peru, Portugal, Romania, USA, New Zealand, and Argentina)

Item	Type	Description
A. Saw a vision	**1**	Did you ever see something that other people who were there could not see.
	1a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?
B. Hearing voices	**2**	Did you ever hear things that other people said did not exist, like strange voices coming from inside your head talking to you or about you, or voices coming out of the air when there was no one around.
	2a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?
C. Thought insertion	**3**	Did you ever believe that some mysterious force was inserting many different strange thoughts -- that were definitely not your own thoughts – directly into your head by means of x-rays or laser beams or other methods?
	3a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?
D. Mind control/passivity	**4**	Did you ever feel that your mind had been taken over by strange forces with laser beams or other methods that were making you do things you did not choose to do.
	4a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?
E. Ideas of reference	**5**	Did you ever believe that some strange force was trying to communicate directly with you by sending special signs or signals that you could understand but that no one else could understand. Sometimes this happens by special signs coming through the radio or television.
	5a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?
F. Plot to harm/follow	**6**	Did you ever believe that there was an unjust plot going on to harm you or to have people follow you that your family and friends did not believe existed?
	6a	Did this every happen when you were not dreaming, not half-asleep, and not under the influence of alcohol or drugs?

Note: For the assessment of psychotic experiences we included items 1a, 2a, 3a, 4a, 5a, and 6a. Similarly for the assessment of hallucination experiences, we included types 1a and 2a, and for the assessment of delusional experiences we included types 3a, 4a, 5a, and 6a.

Supplementary table S2c. 21 DSM-IV mental disorders across 16 WMH sites

A.	**Mood disorders**	Major depressive disorder
		Bipolar disorder (Bipolar I, II, Subthreshold)
B.	**Anxiety disorders**	Panic disorder
		Generalized anxiety disorder
		Specific phobia
		Social phobia
		Agoraphobia without panic
		Post-traumatic stress disorder
		Separation anxiety disorder (Child)
		Separation anxiety disorder (Adult)
C.	**Behaviour disorders**	Intermittent explosive disorder
		Attention deficit disorder
		Oppositional defiant disorder
		Conduct disorder
D.	**Eating disorders**	Anorexia nervosa
		Bulimia nervosa
		Binge eating disorder
E.	**Substance-use disorders**	Alcohol abuse
		Alcohol dependence
		Drug abuse
		Drug dependence

Supplementary table S3a. Associations between temporally prior psychotic experiences (PEs) and the subsequent onset of general medical conditions (GMCs) with additional adjustment for smoking history

Type of GMCs	Any PE		Number of PE types								PE Frequency metric	
			Exactly 1 PE type		Exactly 2 PE types		3 or more PE types		Joint significance of the 3 number-of-PE type measures		> 0·3 episodes/year	
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	χ^2_3	[p-value]	OR	(95% CI)
I. No adjustment for antecedent mental disorders[a]												
Arthritis	1·7*	(1·5-2·0)	1·6*	(1·3-2·0)	2·1*	(1·4-3·0)	2·3*	(1·4-3·8)	χ^2_3 = 48·8*	P <·001	1·8*	(1·3-2·3)
Back or neck pain	1·7*	(1·5-2·0)	1·6*	(1·4-1·9)	1·9*	(1·3-2·8)	2·2*	(1·4-3·5)	χ^2_3 = 49·6*	P <·001	1·9*	(1·5-2·4)
Frequent or severe headaches	1·7*	(1·5-2·0)	1·6*	(1·3-2·0)	1·7*	(1·2-2·4)	3·1*	(2·1-4·7)	χ^2_3 = 69·9*	P <·001	2·3*	(1·8-2·9)
Other chronic pain	2·3*	(1·8-2·9)	2·1*	(1·6-2·7)	2·9*	(1·7-5·0)	2·1*	(1·1-3·8)	χ^2_3 = 45·1*	P <·001	2·2*	(1·7-3·0)
Heart disease	1·9*	(1·4-2·4)	1·7*	(1·2-2·4)	2·2*	(1·4-3·4)	3·2*	(1·1-9·4)	χ^2_3 = 25·3*	P <·001	2·2*	(1·4-3·4)
High blood pressure	1·4*	(1·2-1·7)	1·3*	(1·0-1·6)	1·8*	(1·1-2·9)	1·9	(1·0-3·8)	χ^2_3 = 14·4*	P = 0·002	1·6*	(1·2-2·1)
Asthma	1·3	(1·0-1·7)	1·2	(0·8-1·7)	1·6	(1·0-2·7)	1·1	(0·5-2·4)	χ^2_3 = 4·4	P = 0·223	1·8*	(1·1-2·7)
Diabetes	1·7*	(1·2-2·3)	1·9*	(1·3-2·7)	1·1	(0·6-2·2)	0·9	(0·4-2·5)	χ^2_3 = 12·5*	P = 0·006	2·3*	(1·4-3·8)
Peptic ulcer	1·8*	(1·4-2·4)	1·7*	(1·2-2·3)	1·4	(0·8-2·5)	5·8*	(2·6-12·9)	χ^2_3 = 28·9*	P <·001	1·9*	(1·2-3·1)
Cancer	1·1	(0·8-1·5)	1·1	(0·8-1·6)	1·1	(0·5-2·4)	1·8	(0·7-4·5)	χ^2_3 = 2·0	P = 0·573	1·4	(0·9-2·2)
Other chronic lung diseases	1·5	(0·8-3·1)	0·9	(0·5-1·6)	3·8*	(1·3-11·1)	3·0*	(1·1-7·9)	χ^2_3 = 10·1*	P = 0·017	1·2	(0·5-2·8)
Stroke	1·4	(0·9-2·3)	1·4	(0·8-2·3)	1·9	(0·7-5·5)	-[c]	-[c]	-[c]	-[c]	1·8	(0·7-4·4)
II. Adjusted for antecedent mental disorders[b]												
Arthritis	1·5*	(1·3-1·8)	1·5*	(1·2-1·8)	1·8*	(1·4-2·4)	1·6	(0·9-2·9)	χ^2_3 = 33·2*	P <·001	1·5*	(1·1-2·0)
Back or neck pain	1·5*	(1·3-1·8)	1·5*	(1·2-1·8)	1·7*	(1·3-2·3)	1·4	(0·9-2·4)	χ^2_3 = 28·7*	P <·001	1·6*	(1·3-2·0)
Frequent or severe headaches	1·5*	(1·2-1·7)	1·4*	(1·2-1·8)	1·4*	(1·0-1·9)	2·0*	(1·3-3·1)	χ^2_3 = 28·0*	P <·001	1·8*	(1·4-2·3)
Other chronic pain	1·8*	(1·4-2·4)	1·8*	(1·4-2·3)	2·2*	(1·3-3·8)	1·1	(0·5-2·2)	χ^2_3 = 25·0*	P <·001	1·7*	(1·3-2·4)
Heart disease	1·7*	(1·3-2·2)	1·6*	(1·1-2·2)	1·8*	(1·1-3·1)	2·7	(0·9-7·9)	χ^2_3 = 14·0*	P = 0·003	2·0*	(1·2-3·1)
High blood pressure	1·3*	(1·1-1·5)	1·2	(1·0-1·5)	1·5	(1·0-2·4)	1·5	(0·8-2·9)	χ^2_3 = 7·8	P = 0·050	1·4*	(1·1-1·9)
Asthma	1·2	(0·9-1·6)	1·1	(0·8-1·6)	1·5	(0·9-2·4)	0·9	(0·4-2·0)	χ^2_3 = 2·6	P = 0·456	1·6*	(1·0-2·5)
Diabetes	1·6*	(1·1-2·2)	1·8*	(1·2-2·6)	1·0	(0·5-2·0)	0·8	(0·3-2·1)	χ^2_3 = 10·4*	P = 0·015	2·1*	(1·2-3·5)
Peptic ulcer	1·5*	(1·1-2·0)	1·5*	(1·0-2·0)	1·2	(0·7-2·0)	4·0*	(1·7-9·6)	χ^2_3 = 13·3*	P = 0·004	1·6*	(1·0-2·6)
Cancer	1·0	(0·8-1·4)	1·0	(0·7-1·5)	1·0	(0·4-2·1)	1·4	(0·6-3·6)	χ^2_3 = 0·6	P = 0·899	1·3	(0·8-2·0)
Other chronic lung diseases	1·3	(0·6-2·7)	0·8	(0·4-1·3)	3·0	(0·8-10·9)	2·2	(0·8-5·7)	χ^2_3 = 5·6	P = 0·135	1·0	(0·5-2·2)
Stroke	1·2	(0·7-2·0)	1·2	(0·7-2·1)	1·6	(0·6-4·7)	-[c]	-[c]	-[c]	-[c]	1·6	(0·6-4·1)

OR, odds ratio; CI, Confidence interval

*Significant at the .05 level, 2-sided test.

[a]PE (any PE, number of PE types and PE frequency metric) was used as a predictor of general medical condition outcomes in separate discrete-time survival models. These models control for age-cohorts, gender, person-year dummies, country, and smoking history.

[b]These models additionally control for 21 antecedent mental disorders. See supplementary table S2c for the list of mental disorders.

[c]Unstable estimates due to small cell counts.

Supplementary table S3b. Associations between temporally prior general medical conditions (GMCs) and the subsequent onset of psychotic experiences (PEs) with additional adjustment for smoking history

	Bivariate model[a]		Multivariate model (M1)[b]		Multivariate model (M2)[c]		Multivariate model (M3)[d]		Multivariate model (M4)[e]	
	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)	OR	(95% CI)
I. Type of GMCs										
Arthritis	1·9*	(1·5-2·5)	1·4*	(1·1-1·9)	-	-	1·4*	(1·0-2·0)	1·4	(1·0-2·0)
Back or neck pain	1·9*	(1·5-2·3)	1·4*	(1·1-1·8)	-	-	1·4*	(1·0-1·9)	1·3	(0·9-1·7)
Frequent or severe headaches	2·1*	(1·7-2·5)	1·7*	(1·4-2·1)	-	-	1·7*	(1·4-2·2)	1·5*	(1·2-1·9)
Other chronic pain	2·6*	(2·0-3·4)	1·9*	(1·5-2·5)	-	-	2·0*	(1·4-2·8)	1·7*	(1·2-2·4)
Heart disease	1·5	(0·9-2·4)	1·0	(0·6-1·7)	-	-	1·1	(0·6-1·8)	1·0	(0·6-1·7)
High blood pressure	1·7*	(1·2-2·3)	1·3	(1·0-1·9)	-	-	1·4	(1·0-2·0)	1·3	(0·9-1·9)
Asthma	1·8*	(1·4-2·3)	1·7*	(1·3-2·2)	-	-	1·6*	(1·2-2·2)	1·6*	(1·1-2·1)
Diabetes	1·1	(0·7-1·9)	0·9	(0·5-1·5)	-	-	0·9	(0·5-1·5)	0·9	(0·5-1·5)
Peptic ulcer	1·7*	(1·2-2·4)	1·3	(0·9-1·8)	-	-	1·3	(0·9-2·0)	1·2	(0·8-1·8)
Cancer	1·5	(0·9-2·6)	1·2	(0·7-2·1)	-	-	1·3	(0·8-2·2)	1·2	(0·7-2·1)
Other chronic lung diseases	0·9	(0·4-1·9)	0·6	(0·3-1·2)	-	-	0·6	(0·3-1·3)	0·5	(0·2-1·2)
Stroke	1·1	(0·5-2·6)	0·8	(0·4-1·7)	-	-	0·9	(0·4-1·8)	0·9	(0·4-1·9)
Joint significance of all GMCs, χ^2_{12} [p - value]		N/A		$\chi^2_{12} = 68{\cdot}4$*, p < ·001		N/A		$\chi^2_{12} = 41{\cdot}9$*, p < ·001		$\chi^2_{12} = 27{\cdot}3$*, p = 0·007
Difference between GMCs, χ^2_{11} [p - value]		N/A		$\chi^2_{11} = 27{\cdot}3$*, p = 0·004		N/A		$\chi^2_{11} = 24{\cdot}4$*, p = 0·011		$\chi^2_{11} = 17{\cdot}8$, p = 0·086
II. Number of GMCs										
Exactly 1 GMC		- -		- -	1·6*	(1·3-2·0)	-	-	-	-
Exactly 2 GMCs		- -		- -	2·9*	(2·2-3·8)	1·3	(0·9-1·9)	1·3	(0·9-1·8)
Exactly 3 GMCs		- -		- -	3·1*	(2·2-4·4)	0·9	(0·5-1·7)	0·9	(0·5-1·6)
4 or more GMCs		- -		- -	4·2*	(3·1-5·8)	0·8	(0·3-1·9)	0·8	(0·3-1·8)
Joint significance of number-of-GMCs, χ^2_4 [p - value]		N/A		N/A		$\chi^2_4 = 111{\cdot}8$*, p < ·001		$\chi^2_4 = 6{\cdot}0$, p = 0·113		$\chi^2_4 = 6{\cdot}3$, p = 0·099

OR, odds ratio; CI, Confidence interval

*Significant at the .05 level, 2-sided test.

[a]Each model was estimated with one GMC entered at a time as predictor of PE onset controlling for country, person-year dummies, age-cohorts, sex, and smoking history.

[b]M1: Model was estimated with dummy variables for all GMC entered simultaneously as predictors of PE onset including the controls specified in (a).

[c]M2: Model was estimated with dummy variables for all number of GMC without any information about type entered simultaneously as predictors of PE onset including the controls specified in (a).

[d] M3: Model was estimated with dummy variables for type and number of GMC (exactly 2 GMCs,.., 4 or more GMCs) entered simultaneously as predictors of PE onset including the controls specified in (a).

[e]M4: Model was estimated with dummy variables for type and number of GMC (exactly 2 GMCs,.., 4 or more GMCs) entered simultaneously as predictors of PE onset including the controls specified in (a) and 21 antecedent mental disorders.

Supplementary table S4. Mean and median age-of-onset of general medical conditions (GMC) across 16 WMH sites

General medical conditions	Age-of-onset	
	Mean (SE)	Median
Arthritis	40.7 (0.4)	39.9
Back or neck pain	32.1 (0.3)	29.2
Frequent or severe headaches	25.7 (0.3)	21.8
Other chronic pain	32.6 (0.4)	29.2
Heart disease	49.7 (0.6)	51.7
High blood pressure	46.2 (0.3)	47.1
Asthma	22.0 (0.6)	14.3
Diabetes	48.7 (0.5)	50.0
Peptic ulcer	33.8 (0.4)	29.9
Cancer	50.1 (0.8)	49.9
Other chronic lung diseases	42.0 (1.2)	42.4
Stroke	54.1 (0.7)	57.0